Protagen to ID Protein Biomarkers in Support of Biogen's MS Drug Development Work

The company will use its UNIarray protein array platform to retrospectively analyze samples from a clinical trial in hopes of finding predictive and response biomarkers for relapsing/remitting multiple sclerosis.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.